Raleigh, NC, May 15, 2008 – INC Research®, Inc., a therapeutically-focused contract research organization (CRO) with a process for delivering reliable results, today announced that David Gill and William Hall have been elected to its Board of Directors. Both new members bring necessary expertise to help guide the company’s strategic growth plans.
David Gill, former CFO of NxStage Medical, Inc., will also serve as the chairman of INC Research’s Audit Committee, which has the responsibility to ensure the integrity of financial statements and performance of internal and external audits. Gill has held various executive roles with emerging medtech and information technology companies, where during his tenure revenue and shareholder value significantly increased. Gill has been a frequent presenter at investment conferences and is well known within the healthcare industry.
Hall is co-founder and chairman of Procyon Technologies, Inc., a Chicago-based holding company. He also currently serves as an adjunct professor at the Ross School of Business Administration and as a member of the Leadership Council of the Life Sciences Institute at the University of Michigan. Previously Hall served as chairman and CEO of Falcon Building Products, a subsidiary of Eagle Industries, a privately held $2.4 billion diversified manufacturing company founded by investor, Sam Zell.
“We are privileged to welcome such strong talent to our Board during this exciting period of growth,” said James Ogle, CEO of INC Research. “David brings a tremendous amount of financial expertise and executive experience from the life sciences industry, and Bill provides a unique strategic perspective based on his background in both academic and business leadership roles. After our extensive search, with the addition of David and Bill, we feel we have the right people in place to truly take INC Research to the next level.”
About INC Research® Inc.
INC Research is a therapeutically-focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric trials. The company’s “The Trusted Process®” methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina, with 25 office locations and a presence in 32 countries worldwide. For more information please visit www.incresearch.com.
###
Media contact:
Trisha Vonder Reith
tvonder@incresearch.com
858-597-6418
|
|
|
Bio-Rad Launches Two Bio-Plex Pro Wash Stations
